2024年9月25日 · Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function. …

Share your videos with friends, family, and the world

There is a huge unmet need for therapies that can prevent or reverse fibrosis to modify the progress of disease. Monash researchers Prof Siew Chai, Dr Tracey Gaspari, Prof Rob …

2021年10月18日 · Inosi is developing a new therapeutic approach to treat fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of …

Inosi Therapeutics is developing therapies to address fibrosis, potentially preventing or reversing tissue damage, scarring and a loss of organ function in patients. Their novel inhibitors target a …

2021年10月21日 · Inosi Therapeutics, a university spinout developing technology to treat fibrosis, today announced a $1.5 million seed round, led by IP Group and Monash University (through …

2019年2月20日 · IP Group and Monash University invest $1.5 million into Inosi Therapeutics & $704K funding from TTRA Melbourne, 21 October 2021 Inosi Therapeutics, a university …

Inosi’s novel small molecule inhibitors have been shown to reverse age- mediated cardiac and renal fibrosis, and improve organ function in aged mice. The compounds have also been …

Information on valuation, funding, cap tables, investors, and executives for Inosi Therapeutics. Use the PitchBook Platform to explore the full profile.

Inosi Therapeutics is developing Insulin Regulated Aminopeptidase (IRAP) inhibitors aimed at treating fibrosis-related diseases, including diabetes-induced kidney disease and …